David V. Elkins - Dec 31, 2021 Form 4 Insider Report for BRISTOL MYERS SQUIBB CO (BMY)

Role
EVP, Chief Financial Officer
Signature
/s/ Lisa A. Atkins, attorney-in-fact for David V. Elkins
Stock symbol
BMY
Transactions as of
Dec 31, 2021
Transactions value $
-$1,511,738
Form type
4
Date filed
1/4/2022, 05:22 PM
Previous filing
Dec 6, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMY Common Stock, $0.10 par value Options Exercise $0 +47.4K +56.23% $0.00 132K Dec 31, 2021 Direct F1
transaction BMY Common Stock, $0.10 par value Tax liability -$1.51M -24.2K -18.41% $62.35 107K Dec 31, 2021 Direct F2
holding BMY Common Stock, $0.10 par value 200 Dec 31, 2021 BMS Savings and Investment Program F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMY Restricted Stock Units Options Exercise $0 -47.4K -100% $0.00* 0 Dec 31, 2021 Common Stock, $0.10 par value 47.4K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the Merger, all outstanding Celgene Corporation Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.
F2 Shares withheld for payment of taxes upon vesting of awards.
F3 Based on recent 401(k) plan statement.
F4 Each restricted stock unit converts into one share of common stock upon vesting.